Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...
For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
This page features the latest news about the Denali Capital Acquisition share. Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination Denali Capital ...
That's all for our live coverage of the war in Ukraine. We'll be back tomorrow with more updates. Here's a rundown of the key lines from today: Ukraine's military has said it was responsible for a ...
Fast-growing wildfires raging in Los Angeles killed at least two people on Wednesday, destroying hundreds of buildings, scorching hillsides and prompting officials to order some 70,000 people to ...
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
Copyright 2025 The Associated Press. All Rights Reserved. Mexico’s president on Wednesday responded sarcastically to Donald Trump’s proposal to change the name of ...
Greek-American actor John Stamos marked his nameday on January 7, with a post reflecting on his Greek heritage and the influential people in his family bearing the same first name. "Today I celebrate ...